Zoetis (XSWX:ZTS) 5-Year EBITDA Growth Rate: 10.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:ZTS Zoetis Inc XSWX:ZTS
60 GF Score
Price CHF61.79
GF Value CHF152.55
Valuation Significantly Undervalued
View Full Analysis

What is Zoetis 5-Year EBITDA Growth Rate?

Zoetis XSWX:ZTS 60 5-Year EBITDA Growth Rate is 10.00% as of Mar. 2026. GuruFocus rates XSWX:ZTS with a GF Score™ of 60/100 and a GF Value™ of CHF152.55 (Significantly Undervalued).

Zoetis's EBITDA per Share for the three months ended in Mar. 2026 was CHF1.75.

During the past 12 months, Zoetis's average EBITDA Per Share Growth Rate was 7.50% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 8.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 10.00% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 15.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Zoetis was 677.80% per year. The lowest was -2.80% per year. And the median was 14.55% per year.

Zoetis  (XSWX:ZTS) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Zoetis 5-Year EBITDA Growth Rate Related Terms

XSWX:ZTS vs UTHR, VTRS, NBIX: 5-Year EBITDA Growth Rate Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zoetis 5-Year EBITDA Growth Rate vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zoetis's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Zoetis's 5-Year EBITDA Growth Rate falls into.


XSWX:ZTS
60GF Score
Zoetis Inc XSWX:ZTS
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zoetis 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 10.00% mean?
Zoetis (XSWX:ZTS) has a 5-Year EBITDA Growth Rate of 10.00% as of Mar. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Zoetis and its competitors.
Is Zoetis' 5-Year EBITDA Growth Rate too high?
Zoetis' current 5-Year EBITDA Growth Rate is 10.00%. Overall, Zoetis has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zoetis' 5-Year EBITDA Growth Rate compare to UTHR and VTRS?
Zoetis' 5-Year EBITDA Growth Rate of 10.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Drug Manufacturers company?
A good 5-Year EBITDA Growth Rate depends on the Drug Manufacturers industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Zoetis and its competitors. Zoetis's current 5-Year EBITDA Growth Rate is 10.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zoetis stock overvalued right now?
Based on GuruFocus' analysis, Zoetis (XSWX:ZTS) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF152.55, compared to a current price of CHF61.79 — trading 59.5% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 10.00%. Zoetis' overall GF Score™ is 60/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Zoetis (XSWX:ZTS), the current 5-Year EBITDA Growth Rate is 10.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zoetis (XSWX:ZTS) Overvalued in 2026?

Based on GuruFocus' analysis, Zoetis stock appears to be undervalued. The current stock price of CHF61.79 is trading 59.5% below its estimated GF Value™ of CHF152.55. GuruFocus considers Zoetis to be Significantly Undervalued.

Key valuation signals for XSWX:ZTS:

  • 5-Year EBITDA Growth Rate: 10.00%
  • GF Value™: CHF152.55 vs. price of CHF61.79 (59.5% below fair value)
  • GF Score™: 60/100

No single metric tells the full story. See the XSWX:ZTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zoetis Business Description

Address 10 Sylvan Way, Parsippany, NJ, USA, 07054
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
60GF Score

Get the complete analysis for XSWX:ZTS

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF61.79
Price
CHF152.55
GF Value